The Medicines and Healthcare Regulatory Agency said the risk associated with this type of blood clot is “very small” and that the public should continue to take up the vaccine when offered it.
The agency said late Friday the cases relate to the period up to March 24, during which 18.1 million doses of the vaccine had been administered and that it hadn’t received any similar reports with regard to the Pfizer-BioNTech vaccine.
Concerns over the AstraZeneca vaccine prompted some countries including Canada, France, Germany and the Netherlands to restrict its use to older people.
EU drug regulator chief says no evidence to support restricting use despite reports of rare blood clotting
The World Health Organization has urged countries to continue using the jab.
© 2021 The Canadian Press